The value of antenatal cardiotocography in the management of high-risk pregnancy: a randomized controlled trial.
The value of routine regular antenatal cardiotocography (CTG) in the management of high-risk pregnancy was assessed in a prospective randomized controlled study of 353 patients. All patients had a weekly CTG trace during the last 6 weeks of pregnancy and according to the random allocation the tracings were concealed from, or available to, the clinicians. Other methods of assessing fetal welfare were available to both groups. There was no significant difference between the concealed and revealed groups in the timing and mode of delivery, birthweights, Apgar score and neonatal morbidity. No apparent effect from the routine use of antenatal CTG in high-risk pregnancy was shown.
D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D001724:Birth Weight; D002986:Clinical Trials as Topic; D036861:Delivery, Obstetric; D005260:Female; D005313:Fetal Death; D005318:Fetal Heart / Q000473:pathology / Q000502:physiology*; D005323:Fetal Monitoring / Q000379:methods*; D006339:Heart Rate; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis*; D011446:Prospective Studies; D011897:Random Allocation; D012306:Risk